Terminated NCT01677182
This study exists to explore whether the medication Ramelteon could improve care and understanding. Researchers are trying to understand whether the medication Ramelteon can give earlier or clearer feedback during care.
In United Kingdom Bipolarity Drug i A study involving a medication or substance. From 18 Years to 75 Years
Countries United States, United Kingdom, Bulgaria, ...
Sponsor Takeda
Condition Bipolarity Completed NCT01922258
This study is completed in the United States, in France, in Canada, .... It is testing flexible Dosing of Brexpiprazole for Mental health.
In United Kingdom Mental health Drug From 55 Years to 90 Years
Countries United States, France, Canada, ...
Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition Mental health Completed NCT02192554
This study is completed in the United States, in France, in Canada, .... It focuses on Mental health.
In United Kingdom Mental health Other
Countries United States, France, Canada, ...
Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition Mental health Completed NCT04158453
This summary needs review. Please check the official study record and contact the research team for details.
In United Kingdom Schizophrenia Drug From 18 Years to 65 Years
Countries United Kingdom
Sponsor Autifony Therapeutics Limited
Condition Schizophrenia Completed NCT02589262
This summary needs review. Please check the official study record and contact the research team for details.
In United Kingdom Schizophrenia Drug From 18 Years to 45 Years
Countries United Kingdom
Sponsor Autifony Therapeutics Limited
Condition Schizophrenia Completed NCT03164876
This study is completed in the United Kingdom. It is testing AUT00206 for schizophrenia.
In United Kingdom Schizophrenia Drug From 18 Years to 50 Years
Countries United Kingdom
Sponsor Autifony Therapeutics Limited
Condition Schizophrenia Completed NCT00743405
This study is completed in the United Kingdom. It is testing GSK1034702 for Schizophrenia.
In United Kingdom Schizophrenia Drug From 18 Years to 55 Years
Countries United Kingdom
Sponsor GlaxoSmithKline
Condition Schizophrenia Completed NCT00908154
This study is completed in the United Kingdom. It focuses on Bipolarity.
In United Kingdom Bipolarity, Depression Drug From 18 Years to 55 Years
Countries United Kingdom
Sponsor Biogen
Condition Bipolarity, Depression Completed NCT06451965
This summary needs review. Please check the official study record and contact the research team for details.
In United Kingdom Depression Behavioral Over 18 Years
Countries United Kingdom
Sponsor University of East Anglia
Condition Depression Completed NCT00237913
This summary needs review. Please check the official study record and contact the research team for details.
In United Kingdom Schizophrenia Drug From 18 Years to 65 Years
Countries France, United Kingdom, Austria, ...
Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition Schizophrenia Terminated ISRCTN93089066
This study was terminated in the United Kingdom. It is testing screening and support for depression.
In United Kingdom Depression Other Over 18 Years
Countries United Kingdom
Sponsor NHS Greater Glasgow and Clyde (UK)
Condition Depression Completed NCT02199704
This summary needs review. Please check the official study record and contact the research team for details.
In United Kingdom Schizophrenia Behavioral From 18 Years to 35 Years
Countries United Kingdom
Sponsor University of Manchester
Condition Schizophrenia